7WCP
REGN icon

71 West Capital Partners’s Regeneron Pharmaceuticals REGN Stock Holding History

71 West Capital Partners’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$322K Buy
516
+182
+54% +$124K 0.01% 302
2026
Q1 		$258K Buy
334
+34
+11% +$26K 0.01% 274
2025
Q4 		$232K Buy
+300
New +$204K 0.01% 239

Other funds holding REGN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

71 West Capital Partners's REGN Position: Q2 2026 in Review

71 West Capital Partners increased its Regeneron Pharmaceuticals (REGN) stake by 54% in Q2 2026, buying an estimated $124K and bringing the position to 516 shares worth $322K. The position accounts for 0.01% of the portfolio, ranked #302.

71 West Capital Partners first reported a position in REGN in Q4 2025 and has held it in 3 quarters since. 1,330 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

  • 71 West Capital Partners held 516 shares of Regeneron Pharmaceuticals worth $322K as of Q2 2026.
  • 71 West Capital Partners bought 182 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $124K.
  • Regeneron Pharmaceuticals made up 0.01% of 71 West Capital Partners's portfolio in Q2 2026, its #302 holding.
  • 71 West Capital Partners first reported a position in Regeneron Pharmaceuticals in Q4 2025 and has held it in 3 quarters since.
  • 1,330 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on 71 West Capital Partners's 13F filing for Q2 2026, filed 4 Aug 2026.